Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20325455 | 0.97 | TSHR (0.54) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20330001 | 0.95 | TSHR (0.59) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20322419 | 0.94 | TSHR (0.57) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21649546 | 0.93 | TSHR (0.49) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20234548 | 0.93 | TSHR (0.56) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20330043 | 0.91 | TSHR (0.54) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20330042 | 0.90 | TSHR (0.49) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20234547 | 0.90 | TSHR (0.45) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20443510 | 0.90 | TSHR (0.47) | TSHRHPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20231221 | 0.90 | TSHR (0.47) | TSHRHPGDMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220515-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2019-08-01 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220515-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | TSHR 3257/4885HPGD 3788/4885MEN1 1077/4885 |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | TSHR 3443/4885HPGD 2784/4885MEN1 2454/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | TSHR 3443/4885HPGD 2784/4885MEN1 2454/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | TSHR 1352/4885HPGD 4518/4885MEN1 3988/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | TSHR 1352/4885HPGD 4518/4885MEN1 3988/4885 |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | TSHR 3257/4885HPGD 3788/4885MEN1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.